779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors

• Aung Naing,
• Emiliano Calvo,
• Chen Zhu,
• Martin Gutierrez,
• Elena Garralda,
• Giovanni Abbadessa,
• Helene Guillemin-Paveau,
• Meijing Wu,
• Raymond Perez,
• Marloes van Dongen,
• Ferry Eskens,
• Morgan Finlay,
• Fatima Menas,
• Ozlem Yildirim

Affiliations

Aung Naing

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Emiliano Calvo

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Chen Zhu

6Sanofi, Cambridge, MA, USA

Martin Gutierrez

5Hackensack University Medical Center, Hackensack, NJ, USA

Elena Garralda

Early Drug Development Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Giovanni Abbadessa

6Sanofi, Cambridge, MA, USA

Helene Guillemin-Paveau

7Sanofi, Paris, Chilly-Mazarin, France

Meijing Wu

6Sanofi, Cambridge, MA, USA

Raymond Perez

8Sanofi, Pennington, NJ, USA

Marloes van Dongen

4Antoni Van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands

Ferry Eskens

5Erasmus University Medical Center, Rotterdam, South Holland, Netherlands

Morgan Finlay

1Hackensack Meridian Health, Hackensack, NJ, USA

Fatima Menas

6Sanofi, Madrid, Madrid, Spain

Ozlem Yildirim

7Sanofi, Cambridge, MA, USA